Effect of WHI-P131/JANEX-1 + MTX on post-BMT survival outcome in a mouse GVL/GVHD model
| Treatment protocol . | MST . | Cumulative proportion surviving (% ± SEM) . | P versus . | ||||
|---|---|---|---|---|---|---|---|
| N . | d . | 15 d . | 30 d . | 60 d . | C . | F . | |
| A. BCL-1 | 5 | 13 | 0 ± 0 | 0 ± 0 | 0 ± 0 | — | — |
| B. BCL-1MTX | 5 | 12 | 0 ± 0 | 0 ± 0 | 0 ± 0 | — | — |
| C. Allogeneic BMT + BCL-1 | 10 | 25 | 100 ± 0 | 20 ± 13 | 0 ± 0 | — | < .0001 |
| D. Allogeneic BMT + BCL-1 → WHI-P131 | 10 | 36 | 100 ± 0 | 100 ± 0 | 40 ± 16 | .0002 | .01 |
| E. Allogeneic BMT + BCL-1 → MTX | 20 | 36 | 100 ± 0 | 80 ± 9 | 40 ± 12 | < .0001 | .01 |
| F. Allogeneic BMT + BCL-1 → WHI-P131 + MTX | 10 | > 60 | 100 ± 0 | 100 ± 0 | 100 ± 0 | < .0001 | — |
| Treatment protocol . | MST . | Cumulative proportion surviving (% ± SEM) . | P versus . | ||||
|---|---|---|---|---|---|---|---|
| N . | d . | 15 d . | 30 d . | 60 d . | C . | F . | |
| A. BCL-1 | 5 | 13 | 0 ± 0 | 0 ± 0 | 0 ± 0 | — | — |
| B. BCL-1MTX | 5 | 12 | 0 ± 0 | 0 ± 0 | 0 ± 0 | — | — |
| C. Allogeneic BMT + BCL-1 | 10 | 25 | 100 ± 0 | 20 ± 13 | 0 ± 0 | — | < .0001 |
| D. Allogeneic BMT + BCL-1 → WHI-P131 | 10 | 36 | 100 ± 0 | 100 ± 0 | 40 ± 16 | .0002 | .01 |
| E. Allogeneic BMT + BCL-1 → MTX | 20 | 36 | 100 ± 0 | 80 ± 9 | 40 ± 12 | < .0001 | .01 |
| F. Allogeneic BMT + BCL-1 → WHI-P131 + MTX | 10 | > 60 | 100 ± 0 | 100 ± 0 | 100 ± 0 | < .0001 | — |
(BALB/cJxC57BL/6J)F1 (H-2d/b) recipients were lethally irradiated (9.5 Gy) and transplanted with BM/S grafts from syngeneic F1 or allogeneic C57BL/6 (H-2b) donors. The survival outcome of different treatment groups was compared. GVHD prophylaxis included WHI-P131 dose (50 mg/kg per day), MTX dose (10 mg/m2 per day), or vehicle alone. P (log-rank test) < .05 was considered significant.